Bio-Techne Corp (TECH) has had an eventful time with noteworthy events such as the release of its Q3 2024 Earnings Call Transcript, the dividend declaration, and various partnerships announced, including that with Thermo Fisher Scientific and Nikon Instruments Inc., as well as acquisitions like Lunaphore and Asuragen. Despite encountering certain obstacles such as lower-than-expected Q4 results, the company has made significant strides, including surpassing 10,000 peer-reviewed publications citing its RNAscope technology. This was further bolstered by its continued investment in growing its business, as evidenced by Mirae Asset Global Investments buying 68,813 shares and BNP Paribas buying 73,453 shares. New CEO, Kim Kelderman, was also appointed alongside other board appointments reflecting a strategic organizational expansion and shifts.
Bio-Techne’s stock value also showed resilience. Despite facing market corrections, the shares scaled 33% above their intrinsic value. The company received several awards, including the CiteAb's ELISA Kit Supplier of the Year and Spatial Biology Innovation Awards, affirming their pivotal role in the biotech industry. In addition, Bio-Techne's advancements such as the patent infringement lawsuit against Molecular Instruments and receiving the European IVDR certification keep reinforcing their position in the marketplace.
Bio-Techne Corp TECH News Analytics from Thu, 07 Jun 2018 07:00:00 GMT to Sun, 14 Jul 2024 08:41:31 GMT - Rating 4 - Innovation 7 - Information 8 - Rumor 5
